Lebrikizumab for Atopic Dermatitis Resubmitted for FDA Appro

The decision by Eli Lilly to resubmit lebrikizumab to the FDA for adults and adolescents with eczema is expected to receive a response in the second half of the year.

Related Keywords

United Kingdom , Japan , Eli Lilly , Facebook , Drug Administration , European Union , Reports First Quarter , Raises Full Year Revenue Guidance , Highlights Pipeline , Complete Response Letter , Lebrikizumab Treatment , Atopic Dermatitis , Sad , Eczema , Lebrikizumab , Fda , Crl , Approval , Resubmission ,